Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation (AZALEA-TIMI 71)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04755283 |
|
Recruitment Status :
Active, not recruiting
First Posted : February 16, 2021
Last Update Posted : November 13, 2023
|
Sponsor:
Anthos Therapeutics, Inc.
Collaborators:
The TIMI Study Group
Laboratory Corporation of America
Information provided by (Responsible Party):
Anthos Therapeutics, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | December 2023 |
| Estimated Study Completion Date : | January 2024 |